Inquiry Basket
CAS No.: 2259318-46-0
Cat No.: BADC-00864
Purity: ≥95%
4.5 
SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
Structure of 2259318-46-0
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
SC-VC-PAB-MMAE is a potent ADC Cytotoxin with Linker composed of monomethyl auristatin E (MMAE) attached via a protease-cleavable SC-VC-PAB ADC Linker. This design ensures the ADC payload remains stable in circulation and is released specifically inside target cells. As a defined ADC Cytotoxin, SC-VC-PAB-MMAE enables precise intracellular delivery of MMAE, supporting efficient microtubule inhibition and cell apoptosis in antigen-positive tumor cells.
The cytotoxic mechanism of SC-VC-PAB-MMAE relies on antibody-mediated internalization into antigen-expressing cells. The Val-Cit-PAB linker is cleaved by lysosomal proteases, releasing MMAE directly inside the cell. This targeted release ensures the ADC payload exerts its microtubule-disrupting activity selectively, which is essential for maintaining therapeutic specificity while reducing systemic toxicity.
SC-VC-PAB-MMAE features a protease-sensitive ADC Linker that provides robust stability during circulation and efficient payload release after internalization. The structure supports conjugation to various antibodies through defined attachment points, producing a uniform ADC Cytotoxin with Linker suitable for controlled cytotoxic delivery. Its chemical properties, solubility, and linker stability make it effective in generating consistent ADC constructs with predictable behavior.
Applications of SC-VC-PAB-MMAE focus on its role as a defined ADC payload-linker combination for generating homogeneous antibody-drug conjugates. Its stable linker and cleavable design allow reliable intracellular MMAE release, enabling reproducible cytotoxic activity in antigen-positive cells. SC-VC-PAB-MMAE is thus an essential component for constructing ADC Cytotoxins with controlled mechanism of action and predictable performance.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00019 | Fmoc-VC-PAB-MMAE | 1350456-56-2 | |
| BADC-00849 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | |
| BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
| BADC-00958 | Amino-PEG4-Val-Cit-PAB-MMAE | 1492056-71-9 | |
| BADC-01348 | Val-Cit-PAB-MMAE TFA salt | 1608127-32-7 | |
| BADC-01435 | N-Ac-Cys-MC-VC-PAB-MMAE | 1628933-80-1 | |
| BADC-01408 | DBM(C6)-VC-PAB-MMAE | 1644228-55-6 | |
| BADC-01459 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 | |
| BADC-01638 | OH-Glu-Val-Cit-PAB-MMAE | 1895916-23-0 | |
| BADC-00855 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 |
What is SC-VC-PAB-MMAE?
SC-VC-PAB-MMAE is a small-molecule linker-payload conjugate consisting of a valine-citrulline protease-cleavable linker coupled to MMAE. It is designed for incorporation into ADCs to enable targeted cytotoxic delivery.
22/3/2019
We would like to know how SC-VC-PAB-MMAE releases its payload.
The SC-VC-PAB-MMAE linker is cleaved by lysosomal proteases after ADC internalization, releasing MMAE in the cytoplasm to induce microtubule disruption and apoptosis in target cells.
7/11/2018
We are interested in understanding the advantages of using SC-VC-PAB-MMAE in ADC design.
SC-VC-PAB-MMAE offers controlled release, high potency, and stability in circulation, supporting the development of precise and effective ADC therapeutics for research and clinical applications.
15/3/2018
Is SC-VC-PAB-MMAE suitable for use with various antibody types?
Yes, SC-VC-PAB-MMAE is compatible with multiple monoclonal antibodies, allowing researchers to create ADCs targeting different antigens while maintaining consistent cytotoxic activity.
13/9/2020
Dear BOC Sciences, what laboratory safety measures do you recommend for SC-VC-PAB-MMAE?
Due to its potent cytotoxicity, SC-VC-PAB-MMAE requires careful handling with appropriate containment, personal protective equipment, and strict adherence to cytotoxic compound safety protocols.
17/11/2022
— Dr. Jason Carter, Senior Scientist (USA)
SC-VC-PAB-MMAE purity and stability were excellent, supporting precise ADC conjugation.
15/3/2018
— Dr. Olivia Bennett, ADC Chemist (UK)
Batch uniformity of SC-VC-PAB-MMAE ensured reproducible cytotoxicity results.
17/11/2022
— Dr. Markus Klein, Medicinal Chemist (Germany)
Fast shipping and thorough QC documentation for SC-VC-PAB-MMAE streamlined lab operations.
13/9/2020
— Dr. Emily Hughes, Biochemist (Canada)
Reliable SC-VC-PAB-MMAE quality allowed uninterrupted multi-step ADC assays.
22/3/2019
— Dr. William Adams, Lead Scientist (USA)
Expert technical guidance for SC-VC-PAB-MMAE improved conjugation efficiency and reproducibility.
— Dr. Sophie Morel, Research Scientist (France)
Consistent SC-VC-PAB-MMAE quality combined with responsive support accelerated experimental progress.
7/11/2018
SC-VC-PAB-MMAE
Required fields are marked with *
SC-VC-PAB-MMAE
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
